The FDA approved Orca Bio’s Tregzi on June 30, making it the first regulatory T cell-based immunotherapy to receive clearance in the agency’s history. The next morning it expanded Casgevy’s label to children as young as two, placing a potentially curative CRISPR gene therapy within reach of approximately 5,500 additional American children with sickle cell disease. Four days earlier, Viridian Therapeutics received approval for Lumvoa as the first thyroid eye disease therapy labeled for both active and chronic disease. Three first-in-class or first-labeled approvals arrived in five days. Acting CBER Director Karim Mikhail signed off on all three.
Orca Bio’s Tregzi Received FDA Approval June 30 as the First Regulatory T Cell-Based Immunotherapy Ever Cleared
The Food and Drug Administration approved Tregzi (allogeneic regulatory T cell immunotherapy with HSPC and T cells, formerly known as Orca-T) on June 30, 2026, for use in matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen in adults with hematological malignancies including acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome. Tregzi is the first cell therapy based on regulatory T cells, a specialized subset of CD4+ immune cells that suppress harmful immune responses, to receive FDA approval. The application was granted Orphan Drug and Regenerative Medicine Advanced Therapy designations.
The approval is based on the Precision-T Phase 3 study, a randomized, open-label, multicenter trial evaluating Tregzi against conventional allogeneic hematopoietic stem cell transplant in 187 patients. At one year, 78% of patients who received Tregzi met the chronic graft-versus-host disease-free survival endpoint, compared with 38.4% of those who received a standard transplant. Serious chronic graft-versus-host disease developed in 12.6% of Tregzi recipients within a year, versus 44% among patients who received a standard transplant. No severe infusion reactions occurred, and no cases of graft failure were observed within the study period. The most common adverse event was infection, consistent with patients undergoing stem cell transplantation generally.
Tregzi works by reformulating the donor blood material before infusion. Rather than transferring a mixed population of stem and immune cells from a matched healthy donor directly into a patient, Orca Bio’s platform selects and purifies regulatory T cells from the donor material to suppress graft-versus-host disease, adds hematopoietic stem and progenitor cells to help the patient rebuild a functioning immune system, and follows with conventional T cells to clear residual cancer cells and support immune recovery. Each dose is manufactured individually for each patient using cells collected from the peripheral blood of an 8/8 HLA-matched donor.
FDA acting CBER Director Karim Mikhail: “Today’s approval offers a genuine new approach that can help reconstitute the immune system while substantially reducing that risk and reflects the promise of what cellular therapy can deliver for patients.” Orca Bio CEO Nate Fernhoff: “We founded Orca Bio on the audacious goal to engineer living medicine.”
Orca Bio is pricing Tregzi at a wholesale acquisition cost of $428,000. The company is a private commercial-stage biotechnology firm headquartered in Menlo Park, California. At the start of 2026 the company disclosed $250 million in new capital from two recent financing rounds, including a Series F that closed in December 2025, with most proceeds earmarked for the Tregzi launch. Fierce Pharma noted that Orca is now one of very few US-based commercial drugmakers that remains privately held, and that the biotech IPO market appears to be opening up with record-breaking listings in mid-2026. Whether a public offering follows the commercial launch is the most proximate capital markets question the Tregzi approval raises.
FDA Expanded Casgevy to Children as Young as Two on July 1, Placing a CRISPR Gene Therapy Within Reach of 5,500 More US Children With Sickle Cell Disease
The Food and Drug Administration issued a supplemental approval for Casgevy (exagamglogene autotemcel) on July 1, 2026, expanding its indication from patients aged 12 years and older to patients aged 2 years and older with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta-thalassemia. Casgevy is co-developed and co-commercialized by Vertex Pharmaceuticals (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP). This is the first gene therapy approved for patients as young as 2 with sickle cell disease, and it is the first CRISPR-based gene therapy cleared for use in young children with any condition.
Sickle cell disease is a genetic disorder of red blood cell hemoglobin that causes episodes of severe pain called vaso-occlusive crises, progressive organ damage, and shortened life expectancy. The expansion to children aged 2 to 11 places a potentially curative treatment within reach of approximately 5,500 additional American children before years of accumulated organ damage can narrow their therapeutic options. FDA acting CBER deputy director Megha Kaushal: “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways.”
Casgevy is administered as a one-time single-dose intravenous infusion using the patient’s own hematopoietic stem cells, edited ex vivo with CRISPR/Cas9 to reactivate fetal hemoglobin production and correct the underlying red blood cell dysfunction. Full myeloablative conditioning chemotherapy is required before treatment, a high-intensity preparatory regimen that destroys the patient’s existing blood cells before the edited cells are infused. Myeloablative conditioning carries a risk of permanent infertility, a factor that weighs heavily in a pediatric population whose families may have limited time to discuss and bank fertility options before beginning the conditioning process.
The wholesale acquisition cost of Casgevy is approximately $2.2 million, among the highest of any approved therapy. Access barriers are structural and well-documented. Medicaid, which covers a disproportionate share of patients with sickle cell disease, has inconsistent coverage policies for one-time gene therapies across states. Specialized treatment centers capable of delivering myeloablative conditioning and cell infusion in pediatric patients are geographically concentrated, creating access gaps for families in rural or underserved areas. Vertex has established outcomes-based payment arrangements with certain payers, but the coverage landscape at the time of the supplemental approval remains incomplete for the newly eligible pediatric population.
Viridian Therapeutics’ Lumvoa Received FDA Approval June 26 as the First Thyroid Eye Disease Therapy Labeled for Both Active and Chronic Disease
The FDA approved Lumvoa (veligrotug-vvze) on June 26, 2026, for Viridian Therapeutics (Nasdaq: VRDN), granting Priority Review under Breakthrough Therapy Designation for the treatment of thyroid eye disease, a rare autoimmune condition that causes painful inflammation and tissue remodeling behind the eyes, leading to proptosis, diplopia, pain, and in some cases vision impairment. Lumvoa is an IGF-1R antagonist, the same mechanism as Tepezza (teprotumumab), but is the first approved therapy in this class to carry labeling that includes Phase 3 data from both active and chronic disease, and the first to show a statistically significant effect on both diplopia response and complete resolution of diplopia across both stages.
The approval is supported by the THRIVE trial in active thyroid eye disease and the THRIVE-2 trial in chronic thyroid eye disease, both pivotal Phase 3 studies. Viridian launched Lumvoa commercially the same day the approval was announced. Physicians can prescribe it immediately, and the ViridianCares patient support program is live with insurance navigation, financial assistance, and dedicated support staff. VRDN jumped more than 10% in after-hours trading on June 26 after the announcement. The company is also advancing elegrobart, a subcutaneous investigational IGF-1R-targeting therapy designed for self-administration via autoinjector, with a biologics license application submission targeted for Q1 2027.
Vera Therapeutics and ENHERTU PDUFA Dates July 7, AbbVie’s $10.9 Billion Atopic Dermatitis Deal, and Generic Tirzepatide Accepted for Review
Vera Therapeutics atacicept PDUFA: July 7
ENHERTU post-neoadjuvant breast cancer PDUFA: July 7
AstraZeneca and Daiichi Sankyo’s ENHERTU (trastuzumab deruxtecan) has a July 7 PDUFA date for a new indication as post-neoadjuvant treatment for patients with HER2-positive early breast cancer. ENHERTU is already approved in HER2-positive metastatic breast cancer and has become one of the fastest-growing oncology assets globally. A positive decision would expand its reach earlier in the treatment pathway.
AbbVie acquires Apogee Therapeutics for $10.9 billion
AbbVie announced the acquisition of Apogee Therapeutics and its atopic dermatitis candidate zumilokibart for approximately $10.9 billion during the coverage window, adding a late-stage IL-13 receptor alpha-1 inhibitor to its immunology portfolio alongside Skyrizi and Rinvoq. The deal is one of the largest biotech acquisitions of 2026 and reflects continued consolidation pressure in dermatology and immunology as biologic patent cliffs approach.
Sandoz ANDA accepted for generic tirzepatide
Sources
- FDA approves new treatment that uses donor immune cells to prevent serious complications in blood cancer patients — FDA press release (primary), June 30 2026
- FDA approves allogeneic regulatory T cell-based immunotherapy for matched donor HSCT — FDA drug approval summary (primary), June 30 2026
- Orca Bio’s TREGZI receives US FDA approval as first and only precision-engineered cell therapy for allogeneic transplant — Orca Bio press release (primary), June 30 2026
- FDA makes a splash with FDA approval for cell therapy Tregzi — Fierce Pharma, June 30 2026
- FDA grants first-in-class approval for Treg cell therapy in blood cancer transplant patients — Pharmaceutical Technology, June 30 2026
- Orca opens up Treg cell therapy with FDA nod for allogeneic blood cancer treatment — BioSpace, June 30 2026
- Orca Bio cell therapy gets landmark FDA nod — MedCity News, June 30 2026
- FDA approves first gene therapy for young children with sickle cell disease — FDA press release (primary), July 1 2026
- FDA approves first gene therapy for young children with sickle cell disease — Globe Newswire (Vertex primary), July 1 2026
- CRISPR sickle cell therapy now cleared for children starting at age two — TechTimes, July 4 2026
- Gene therapy for children with sickle cell disease approved by FDA — The Hill, July 2026
- FDA expands Casgevy label to younger children with sickle cell disease — Epocrates, July 2026
- Viridian Therapeutics announces US FDA approval and launch of Lumvoa — Viridian press release via Business Wire (primary), June 26 2026
- Viridian Therapeutics Form 8-K filed June 26 2026 — SEC EDGAR (primary)
- FDA approves Lumvoa for thyroid eye disease across active and chronic stages — Ophthalmology Times, June 26 2026
- VRDN stock jumps after-hours as Viridian wins first FDA approval — Stocktwits, June 26 2026
- Fierce Pharma regulatory tracker 2026 — Fierce Pharma, updated July 6 2026
- FDA calendar 2026: PDUFA dates — RTTNews
Editorial Disclosure
This analysis is based entirely on publicly available information including FDA press releases, company press releases, SEC filings, and named secondary reporting from named publications. Securities discussed include Vertex Pharmaceuticals Inc. (Nasdaq: VRTX), CRISPR Therapeutics AG (Nasdaq: CRSP), and Viridian Therapeutics Inc. (Nasdaq: VRDN). aktiego.com has not received any compensation from any company mentioned, their management, investor relations representatives, or any third party. No staff member or principal of aktiego.com holds a position in any security mentioned at the time of publication. Orca Bio is a private company. Financial details including the $250 million capital raise and Series F are sourced to named published reports and are not independently verified by aktiego.com. Tregzi WAC of $428,000 is sourced to named published reports citing the company. Orca Bio IPO speculation is attributed to named published reporting (Fierce Pharma) and represents that publication’s commentary, not aktiego.com’s view. Casgevy WAC of approximately $2.2 million is sourced to named published reports and is not independently verified by aktiego.com. Access barrier information regarding Medicaid coverage and geographic concentration of treatment centers is sourced to named published reports. Coverage and access conditions are subject to change. Viridian Therapeutics (Nasdaq: VRDN) VRDN after-hours price movement cited as sourced to named published reports (Stocktwits, The Pharmaletter). Stock price movements are historical and are not predictive of future performance. The elegrobart BLA target of Q1 2027 is a company-stated plan and is not guaranteed. PDUFA dates cited for Vera Therapeutics (Nasdaq: VERA) and ENHERTU are sourced to named published FDA calendar sources. PDUFA dates represent the FDA’s target review completion deadline and do not guarantee approval, denial, or action on any particular date. The AbbVie acquisition of Apogee Therapeutics figure of $10.9 billion is sourced to named published reports and is not independently verified by aktiego.com. Acquisition transactions are subject to regulatory and shareholder approvals. Sandoz ANDA acceptance for generic tirzepatide is sourced to named published reports. ANDA acceptance does not constitute approval. The timing and outcome of the FDA’s review are not guaranteed. Both securities and all assets mentioned carry significant investment risk including total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see our full DISCLAIMER.
Watch on YouTube
